Actively Recruiting
The Effect of Continuous Intravenous Infusion of Lidocaine on Postoperative Pulmonary Complications and Prognosis in Emergency Surgical Patients With Intra-abdominal Infection
Led by Shanghai Zhongshan Hospital · Updated on 2026-04-29
428
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
S
Shanghai Zhongshan Hospital
Lead Sponsor
T
The Affiliated Hospital of Xuzhou Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of a continuous 24-hour intravenous infusion of lidocaine on the occurrence of postoperative pulmonary complications (PPCs) in patients undergoing emergency laparotomy for intra-abdominal infection (IAI). The study also aims to assess how this lidocaine infusion may influence the need for mechanical ventilation, protect key organ functions during surgery, reduce hospital stay length, and affect outcomes within 30 days after surgery. Participants are randomly assigned to one of two groups: one receives a loading dose of lidocaine followed by a continuous infusion for 24 hours after surgery, while the other receives an equivalent volume of normal saline as a placebo. Both groups undergo the same anesthesia, pain control, lung-protective ventilation, and other supportive care strategies during the perioperative period. During the study, patients are closely monitored for signs of PPCs within 2 days after surgery, including atelectasis, unplanned ventilation, acute respiratory distress syndrome, and pneumonia. Researchers will also track mechanical ventilation needs, organ function protection, hospital stay duration, and health outcomes for up to 30 days postoperatively. The study involves various assessments such as imaging and blood tests to diagnose complications and evaluate recovery.
CONDITIONS
Brief Title
The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years, any gender
- Patients suspected of digestive tract perforation or obstruction confirmed by imaging requiring emergency surgery
- Receiving general anesthesia
- Patient or family has read and signed informed consent
- Elevated serum procalcitonin or abnormal white blood cell counts indicating inflammation
You will not qualify if you...
- History of allergy to local anesthesia drugs
- Pregnant patients
- Receiving renal replacement therapy
- Presence of arrhythmias, heart failure, second or third-degree atrioventricular block, or low left ventricular ejection fraction
- Preoperative platelet count below 80 x 10^9/L
- Need for secondary surgery due to postoperative anastomotic fistula
- Participation in other clinical studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 day
Participants receive a loading dose of lidocaine or placebo at anesthesia induction, followed by continuous intravenous infusion for 24 hours postoperatively during emergency surgery.
1 surgery and infusion period
Duration - Up to 30 days postoperatively
Participants are monitored for postoperative pulmonary complications and other outcomes up to 30 days after surgery.
Visits as needed during the 30-day postoperative period
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital,Fudan university
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here